Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | SCN1A | P35498 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024208 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL24861312 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL7965361 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL11871085 | 0.87 | SMN1; SMN2 (0.49) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL1143703 | 0.86 | ALDH1A1 (0.48) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL17335022 | 0.85 | TDP1 (0.42) | SMN1; SMN2TDP1L3MBTL1ALDH1A1CYP2C19 | |
| SCHEMBL11398188 | 0.84 | TDP1 (0.56) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL2479192 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL9544732 | 0.82 | CA12 (0.55) | SMN1; SMN2TDP1MAPTALDH1A1LMNA | |
| SCHEMBL4089371 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2TDP1L3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397819-B | PDE4 inhibitor compound and medical application thereof | 苏州隆博泰药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | INNOCURE THERAPEUTICS, INC. (KR) | 2026-02-05 | — | — | US | disclosed |
| US-20260008791-A1 | CHEMICAL COMPOUNDS | BORAH INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4640686-A1 | DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624472-A1 | DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| US-12384756-B2 | Piperidinedione derivatives | INNOCURE THERAPEUTICS, INC. (KR) | 2025-08-12 | — | — | US | disclosed |
| US-12358932-B2 | Chemical compounds | BORAH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250214967-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BERRYBIO SHANGHAI LTD (CN) | 2025-07-03 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6211227-B1 | SULFUR CONTAINING TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-0979821-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-02-16 | — | — | EP | disclosed |
| US-5635517-A | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines | CELGENE CORPORATION (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0002624-B1 | 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
| US-3988340-A | HYPOTENSIVE AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008791-A1 | CHEMICAL COMPOUNDS | JAK3, JAK2, JAK1 | SMN1; SMN2 3880/4885TDP1 615/4885L3MBTL1 3260/4885 |
| US-20260035354-A1 | PIPERIDINEDIONE DERIVATIVES | CRBN, PSMC1, PSME3 | SMN1; SMN2 3555/4885TDP1 4369/4885L3MBTL1 2779/4885 |
| US-20250214967-A1 | FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PTK2, CTTN, SRC | SMN1; SMN2 559/4885TDP1 1629/4885L3MBTL1 4657/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | SMN1; SMN2 818/4885TDP1 1062/4885L3MBTL1 3649/4885 |
| US-12384756-B2 | Piperidinedione derivatives | CRBN, CUL1, PSMB10 | SMN1; SMN2 2650/4885TDP1 4149/4885L3MBTL1 2143/4885 |
| US-12358932-B2 | Chemical compounds | PDE4A, PDE4B, SYK | SMN1; SMN2 2363/4885TDP1 311/4885L3MBTL1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.